Professional Documents
Culture Documents
Afinual Report
^Y: /2013-2014
I .
i
I
I' Libra
ii!,raInfusions Limited
I
An Obsession with Quality
, \i1
In
To the Environment 4
To the World class Quality Products 4
Vision Mission
Libra's vision is to embody global pharmaceutical To attain Vision Libra will devote it's resources to
leadership through innovation, culture and growth manufacture world class products using modern
guided by an unwavering commitment to technology. To maintain Quality Management
significantly improve the lives of patients. System in line with ISO 9001 through
Innovation based on bold leadership in science documentation of all activities of the company for
and medicine resulting in the discovery, development of employees at all levels by regular
development and delivery of high-quality, training and participation.
differentiated products focused on patient needs.
A culture based on good corporate citizenship that To satisfy our customers through service upto their
empowers employees through collaboration, level of expectation.
inclusion, trust and timely decision making.
Sustainable growth in corporate value by Libra reviews activities and performance of it's
leveraging core therapeutic areas, and an operation to ensure compliance with objectives.
industry-leading pipeline and product portfolio.
I
IA I
•1N
SalesCentre o^
Lib^
rainf^
usio^
ns td.
Panchagarh'
Thakurgaon( j JiIphan1ari\
/'o 7?
/ J
2
Bay of Bengal
a,
Transmittal Letter (H Message from the Chairperson
o Corporate Governance
Quality Management System I
Compliance Report
Research and
Statement of Financial Position
Development Facilities
Statements on Duties of
Managing Director (CEO) & CEO
II
i• u •u•i
I..
I •iu•
'III...
•uuuiuu
The Shareholders
The Chairman, Bangladesh Securities and Exchange Commission
The Registrar of Joint Stock Companies & Firms
The CEO, Dhaka Stock Exchange Ltd.
The CEO, Chittagong Stock Exchange Ltd.
We are pleased to enclose a copy of our Annual Report together with the
Audited Financial Statements including Statement of Financial Position as at
30 June 2014 and Statement of Comprehensive Income for the year ended
30 June 2014 along with other Statements and Notes thereon for
your information and record.
Yours sincerely,
Jahangir Alam Dated, Dhaka:
Company Secretary 28 October 2014
AnnuaReport2O13-14tPageO2I
I
Ayesha Alam Dr. Roushon Alam
Chairperson Managing Director & CEO
A
Mian Muhammad Shaheedijllah FCA Md. Mizanur Rahman FCA,FCS M.H. Chowdhury
Nominee Director Independent Director Independent Director
Audit Committee
Mr. Mizanur Rahman FCA,FCS - Chairman
Ayesha Alam - Member
Dr. Roushon Alam - Member
Mr. M.H. Chowdhury ii1I1i
Auditors
Management Committee Atik Khaled Chowdhury
Dr. Roushon Alam - Chairman Chartered Accountants
Man Muhammad Shaheedullah FCA -Member Hasan Court (1st Floor)
Monami Alam Member
-
23/1 Motijheel C/A
Dhaka- 1000.
Company Secretary Bankers
Mr. Jahangir Alam Al-Arafa Islami Bank Ltd.
Prime Bank Ltd.
Chief Financial Officer (CFO) Dutch Bangla Bank Ltd.
Mr. A.N.M. Mainuddin Premier Bank Ltd.
Sonali Bank Ltd.
Head of Internal Auditor (H IA)
Insurers
Mr. Moklesur Rahman
Green Dulta Insurance Co,Ltd.
Republic Insurance Co.Ltd.
L . - •
U lUll
11l1U1
hull.
I..
Abwaa ifil.
/ Now
/ •cu U
U1
mamma
mumuar
ma
Research & Development Facilities As a result of our efforts in R & D we have
been successful in developing and
The aim of pharmaceutical research and introducing quality products faster than our
development facility is to design a quality competitors. We have built up a
product and its manufacturing process to sophisticated R & D facility equipped with
consistently deliver the intended state-of-the-art equipment and facilities.
performance of the product which our Our R & D is a highly experienced
strategy to introduce new products and multidisciplinary team. The objective of this
delivering quality products to customers R & D strength is to develop new drug
stand ond can be updated to support new delivery system.
knowledge gained over the lifecycle of a
product. The R&D section is intended to Libra Infusion's Limited is a well decorated
organizational structure. This R&D
provide a comprehensive understanding of expansion will allow the rapid growth of
the product and manufacturing process for clinical programs and aims to encompass
reviewers and inspectors. R&D section all activities, from drug-target identification
provides an opportunity to demonstrate a to late-stage clinical studies.
higher degree of understanding of material
attributes, manufacturing processes, and
their controls. This scientific understanding
facilitates establishment of an expanded
design space. In these situations,
opportunities exist to develop more flexible d -
r jr
regulatory approaches to facilitate:
rp Risk-based regulatory decisions (reviews
and inspections).
Manufacturing process improvements,
within the approved design space
described in the dossier, without further
_1........- £.
regulatory review. New product in process
Reduction of post approval submissions. We are always dedicated to serve the nation
Real-time Quality Control, leading to a for healthier, happier & longer lives by
reduction of end-product release testing. providing world class life saving products. Our
aim is to support ailing people by introducing
new product day by day which will also
increase our total revenue.
I
To extend our product range, we are launching
5
infusion giving set and we have earned good
reputation in the market. All formalities have
been done for Amino Acid l.V, Disposable
Syringe & within a very short period of time we
will be able to introduce some new product like
Blood Bag, Urine Bag, Anti Cancer Drug,
Medical Plaster, Medical Tapes, Blood Vacuum
111 Tube, Transfusion Set etc.
The whole world is now under threat of heavy pollution and ecological imbalance,
Bangladesh is also no exception to that. But the world as a whole is trying to maintain its
characteristic and criteria in every stage making to loop that stabilizes the environment
system. With the growing need of increased population and industrial revolution can not
be denied. This has created tremendous pressure on the ecological balance by breaking
the loop. However, using the modern technology, the eco balance loop is being least
disturbed with the friendly environmental behavior of industrial outlets but undoubtedly
with further threat.
Taking the whole situation into consideration the Company has set up the indusf,y in
Mirpur, an area identified as Industrial zone adjacent to the National Garden with utmost
care against health hazards to the neighboring people living outside the industrial belt.
The Factory is set up on 1.69 acres of land, Administrative, Quality Control and Factory
buildings are quite separate maintaining adequate distance as per requirement under
the regulations of RAJUK. The Factory is under constant cleaning process with sufficient
number of cleaners using modern equipment and best medicines for the purpose. The
Company always maintain and continue to upgrade its Safety, Health and Environment
(SHE) system is accordance with and in anticipation of regulatory requirements and global
developments.
Factory drainage system is well planned and bases on modern concept. The mechanism
and internal environment of the operation for the production of life saving I.V. Fluid is
pleasanr. Moreover, set-up a world class Effluent Treatment Plant (ETP) will be completed
within shortest possible time.
The Company maintains a high standard of Fire Fighting Equipment as per law. The experts
of Civil Defense Department, Ministry of Labour and Manpower and the Ministry of
Environment visit the Factory regularly and expressed their deep satisfactory over the
maintenance standard.
(5% Dextrose in aqua w/v), 500011 & 10000371. (Hartmann's Solution), 500m1 & 1000mI.
For rehydration at the time of water deficit, Mainly used as a fluid and electrolyte
general weakness and post surgical replenisher in hypovolaemia caused by
intervention. trauma surgery, haemorrhage and burn
weakness, eclarnpsia, pre-eclampsia, during lbhis solution is indicated foi use in adults and
pregnancy & after delivery and post surgical pediatric patients as a source of electrolytes,
intervention. calories and water for hydration
(5% Dextrose w/v+0.9% NaCI w/v), 500m] & 1000ml. (0.9% NaCI w/v),lOOniI,250n1),500m1 & 1000ml
This solution is used for correction of serious
For rehydration during general weakness,
sodium deficit. Its use is essential for
water deficiency along with sodium; diuresis, haemodialysis procedure. It can be used topically
intoxication and poet surgical intervention. for irrigation of wounds and body cavities.
LIBRAZOL ]
(5% Dextrose w/v + 0.45% NaCl w/v), SOOrnl.
It fulfils water deficit along with low grade
deficiency of NaCl for growing children, (Metronidazole 0.5% wlv), lOOmI.
#5 simultaneously it supplies energy. It also The most effective antimicrobial agent for the
excludes the risk of hypernatraemia in adult treatment of anaerobic infections.
where less NaCl deficiency occur.
;) r
(5% Dextrose wlv+0.225% NaCl wlv), 250ml & 500m1. (Ciprofloxacin 0.2% w/v), lOOmI.
It fulfils both water deficit along with low grade The most active and potent fluoroquinolone for
deficiency of NaCl for neonates & infants, the treatment of both Gram-positive and
$ simultaneously it supplies energy. It also
Gram-negative bacteria including mixed
1* excludes the risk of hypernatraemia in adult
where less NaCl deficiency occur.
infections.
V.' (10% Dextrose wlv*0 225% NaCl wlv), SOOmI & 1000ml.
This solution is indicated for parenteral
replenishment of fluid, minimal carbohydrate
calories and sodium chloride as required by
the clinical condition of the patients.
(Ciprofloxacin 0.4% wlv), lOOrnI.
The most active and potent fluoroquinolone for
the treatment of severe systemic infections
caused by both Gram-positive and Gram-
negative bacteria including mixed infections.
I wr
The 35th Annual General Meeting (AGM) of the shareholders of Libra Infusions Ltd. was held
on 26 December 2013 at 11.00 a.m in the Corporate Head Office Building-2 (Level-7) of Libra
Infusions Ltd., /7, Mirpur Industrial Estate, Rupnagar, Section-2, Dhaka-1 216, Bangladesh.
The Chairperson thanked the shareholders for their keen interest and continued support
for the Company. The performance of the company in 2012-2013 and the future
strategies were discussed in the meeting. The Shareholders expressed their deep
satisfaction over the progress and activities of the Company and osured their continued
whole hearted support in future development and progress of the Company. The
Chairman of the meeting highly appreciated them for their positive attitude, active
participation and valued suggestions.
P LIBRA INFUSIONS
Gr .i
LIMITED
35 Ir a 2013
s . = a
I l t .; \
Net Assets Value( NAV) 1,966,895 1,961 ,986 1,959,218 1,960,6 12 1,960,892
Price earning Rafio (Tirries) ' , 70.57 56.41 63.25 72.89 30.84
Turnover
Bought-in-Materials & Service
Value Added
Applications
.11,
Duties & Taxes to GOVT. Exchecquer 36 Duties & Taxes to GOVT. Exchecquer 37
Salaries and Benefit to Employees 26 Salaries and Benefit to Employees 25
Interest to Lenders 30 Interest to Lenders 30
Dividend to Shareholders 2 Dividend to Shareholders 2
Earnings Retained by the Company 6 Earnings Retained by the Company 6
It
Libra Infusions Limited
Corporate Headquater:
117, Mirpur l/E (Rupnagar), Section-2, Dhaka-1216, Bangladesh.
p
tibra Phone: 9001179, 9004770-1, 9032534, 9032536 Fax +880-2-9035833
An Ob.n'.,inn with Quality E-mail : libra@libragroupbd.com , Web: www.libragroupbd.com
02 October 2014
i. We have reviewed Financial Statements for the year ended 30 June 2014
of Libra Infusions Ltd. and that to the best of our knowledge and belief;
ii. There are, to the best of our knowledge and be1ief, no transactions
entered into by the Company during the year which are fraudulent, illegal
or in violation of the Company's code of conduct.
L The First and the Largest Manufacturer of l.V. Fluid (Saline) in Bangladesh
1-hi
r_
Annual Report 2Ol3-l4IPage 141
1
I I1II
--
I UMRSE
U-
111111
NOMMMEM
"III
As Salamualaikum
I am most delighted to welcome you to the 36th Annual General Meeting (AGM) of Libra
Infusions Ltd. with the Directors' Report to the Shareholders, the Audited Accounts and
Auditors' Report thereon for the year ended 30 June 2014.
The Company has completed another bright year of operation, fulfilling the avowed
objectives as determined by the Board of Directors.
Business Condition
The ongoing global economic challenges and political turmoils and certain
unprecedented events disrupted our business activities impact having on the economic of
the Company during the year 2013-2014. Consequently effects like increased in
raw-material cost and higher interest rate also weighted on the profitability. Despite these
issues, Libra was able to achieve its reasonable target.
Unit No-2
It is a great pleasure to announce that Unit No-2 of the Company having a 8 storied
Factory Building have since been completed and installation of imported machinery are in
process. We hope by the end of 31 March 2015 Unit No-2 shall be on operation.
Performance
Dear Shareholders, you will be happy to know that the rate of our product has been
increased with the approval of Drug Administration. The Company increased its net
turnover to 1k. 28.23 crores a rise of 24% compared to previous year. In consideration of that
the Board of Directors have been pleased to recommend 20% cash dividend during the
year 2013-2014.
Equity and Shares
During the year 2013-2014, there was fluctuation in our Share Price rate - the highest
quoted share price was Tk.654.00 and the lowest was Tk.247.30 per share of 1k. 10 each.
I want to thank our employees for their innovative approach, attention to the concept of
continuous improvement and royalty.
Last but not the least; I am grateful to the members of the Board for their wise counsel and
keen interest in conducting the affairs of the Company.
Thanking you all with wishes of a good health, prosperity and happiness.
Ayesha Alam
Chairperson
I'
NONE
mom ll
Ill I
U..
I.....
UI....
UU U
rRrt ktiTtT
rn , cic I
iiI 51t
1t 5flW9 o-ko8 T4FtI
i rr *r nrr
cT'fl WI1t9 C1fl fJ 'l I
zi;t
J C 5I1ft9 1t-. b-fl ft j4
wr rf I
i
cii
M-1-111.11tim
^^ I'
• ••••••
• S 5.151
a •uia
Si.
uSual
•uu..a.
Ill
i4#u2 l4eem
Dear Shareholders,
Assalamu Alikum Wa rahmatullahi Wa Barakatuhu. We have the pleasure to welcome you on
behalf of the Board of Directors of the 36th Annual General Meeting of the Libra Infusions Ltd
and present you the Auditors Report, Audited Financial Statement, Statement of
comprehensive income and Cash Flows Statement for the year ended 30 June 2014.
Business Activities
The year 2013-2014 witnessed a gradual retrieval from the worldwide economic recession. This
coupled with the inflation in Bangladesh resulted in continual higher cost of commodities.
The crisis in supply of gas, water and electricity affected national and also our production and
business efforts. Inspite of all these adversities, the company's dynamic leadership and timely
alternative actions combined with boldness and an environment of trust helped on
overcoming the situation. By the grace of almight Allah the Company's overall performance
was satisfactory. The Company's Earning per share (EPS) has increased by 41% from the year
2012-2013 to year 2013-2014.
Particulars
2013-2014 2012-2013
Earnina aer share (Tk.10.00 each Tk.5.92 Tk.4.21
Financial results
The financial results of 2013-2014 are delineate below
Amount in Taka
2 Particulars
013-2014 2012-2013
Profit before tax 10102,998 8,533,220
Less: Income tax (2,690,357) (3,262,1 32)
Profit after tax 7,412,641 5,271,088
Retained earnings as per last accounts 51,265,223 46,207,449
Retained earnings at the end of the ye 52,435,926 51,265,223
ii
••. •
t
MEN .-
NOON U
III
U,,...
UI,...
III
e. The Internal control system was proper and effective application and monitoring was
confirmed.
f. The ability of the company as a going concern has been proved beyond any doubt.
g. There has been no remarkable deviation in the operational affairs as compared to the
previous year.
h The key operating and financial data for preceding 5 years have been shown in the
corporate operational results.
The Corporate governance compliance report has been incorporated as per proforma
supplied by the Bangladesh Securities and Exchange Commission.
j. No IPO or Right issue made during the year 2013-2014.
k. During the year 8 Board Meetings were held and attendance by each Director is shown below:
A Going Concern
The Board of Directors after analysis of the business trend of the company has confirmed
that the Company has enough ability to carry on business activities in the coming days as
a going concern and accordingly the financial statements have been prepared.
Sales and Distribution:
In order to keep the company's sales, marketing, distribution and financial activities
vibrant and dynamic, 13 (thirteen) Sales Depot were being effectively operated with
requisite manpower, independent transport, security measures and computers operated
under the connectivity system. The company is self-assured in increasing the sales,
monitoring, development of territories, efficient control of expenses, enhancing efficiency
and effective distribution system.
Fixed Assets
In the year under review, the company has invested Taka 17 crore 24 lac in acquiring fixed
assets such as building, plant and machinery, furniture & fixture, vehicles etc.
Auditors
The term of our auditors M/s. Atik Khaled Chowdhury, Chartered Accountants is expiring of
this meeting. Being eligible they have expressed their willingness for re-appointment as
auditors of the company for the year 2014-2015. In view of above, the Board of Directors
recommended for approval of the appointment of Atik Khaled Chowdhury.
^^ I!
i
• I ._ ONE
•
PL N NO
til UMIISU
NOONNA
UUU
Internal Control
The board has the ultimate responsibility for Libra Infusions system of internal control and for
reviewing its effectiveness. It has been designed to manage the risk of failure to achieve
the objective of the Company and to provide reasonable assurance that Company's
assets are safe guarded against unauthorized use or material loss and transaction are
properly recorded. As a part of Internal Control procedure, we have introduced 24/7
CCTV in operation for operational control.
Information technology
An Enterprise resource planning (ERR) system was bring out to integrate IRIs production,
marketing, accounts and sales information under a web-based connected MIS system.
With this system target and achievement reports of the marketing field forces are easily
recorded and analysed for decision making as and when required in Head Office. As a
result, the stock and sales reports at countrywide 13 different depots are available to the
management in right time.
Corporate Governance
Corporate Governance is the system through which companies are directed, guided and
controlled by the Board, keeping in view its accountability to the shareholders. Our
Company strives to maintain full compliance with the laws, rules and regulations that
govern our business and to uphold the highest standards.
Audit Committee
The company had an Audit Committee in place with Md. Mizanur Rahman FCA,ECS as
Chairman, Ayesha Alam, Dr. Roushon Alam and Mr. M.H. Chowdhury as members. The
Board subsequently, reconstituted the Committee as follows:
• Md. Mizanur Rahman FCA, FCS Independent Director - Chairman
• Ayesha Alam - Member
• Dr. Roushon Alam - Member
• Mr. M.H. Chowdhury, Independent Director :: - Member
• Mr. Jahangir Alam, Company Secretary - Member Secretary
I'
MENNEN I
MENU • I j
fE VE N U
F
4.
1
LA
Human Resource Development
With a vision to arrive at a top position in the Pharmaceutical Industries and to maintain a
firm and dignified place in the competitive market, various steps were taken by the
Company to train in and outside the country and to arrange workshops in relevant
aspects. Libra's greatest treasure is the human capital-not only individual competence,
expertise, and vision but also their inspired individual vow to the company's mission of
making different in inspiring quality of healthcare in Bangladesh.
Inclusion in CDBL
As per order no.SEC/CDS/206/203/114 dated 23 April 2010 and SEC/CDS/206/203/261
dated August 05, 2010 of Securities and Exchange Commission accordingly the shares of
Libra Infusions Ltd. has been enlisted with CDBL with effect from 31 August 2010 which has
been published as per directives.
Dividend
As stated earlier your Company has taken up the development works of the company and
of the same time the management is much cautions as to its obligation to the owners of
the Company. Keeping the overall situation the management recommends 20.00 %
dividend this year @ Tk.2.00 per share of 1k. 10 each.
Election of Director
As per Article 96 and 97 of the Company's Articles of Association of the Company Shefta
Alam and Mian Muhammad Shaheedullah retire by rotation and being eligible, offer them
for re-election.
Relation and communication with s hare holders
The company has been arranging Annual General Meetings regularly from its inception as
per Companies Act. The Annual General Meeting of the company is a regulatory meeting
through which shareholders are acquainted with the financial results, company's
progrees, important activities and current developments.
ii
1ua.
4JuI I
ll m
I f171
717
rn /
i i int rfli iw ci rrr win cit
*f T 08 I1 Wt\ 5flf
C fn 1NI t, cn ZjZS
1i11II1P I4*N
o-o8 [1 fT W1 Z11 flflt9 T#f TtT J1i
rr i q", -rt1, WNTC ri \s ioic I I1 "\5 I1 T3 P'fltT
c f -zrr
\5 ift
tflI k o - o C1 o-k o 8 Q'ThT 5T 8 1I 'nzFz I
n1
ko-o8 5ffFf T11t1 !K-
o-o 8
-
ob-b-
8,ko,88
n C1Tfl
I1 11f5 (, cJT 8 c li8 5FJ:nt f1f/ 'ii4
ii frrl I
f crMr t1T
fn I
fn cr fn
rr1 I
i. 5flf I
. o -ko o8 ci P0 cn
1cI b- 11 o1 cjrci 2J
trr
31 CTk1N LMI Ob
L T.'5 ob-
trn f, , c c
I C fr T1 i1c f11 ii I
'1'rrc c, i cnf ir
rri cztis fn ii ftrnt rr s P't 1C I c 2ff 1't fuirtt
fr nr cii1 ri
l'1( ti
1irrrn *1i rmit t lr nft I
1 g , 11 CTP'f1 I 1UIi
Operational Control c 51N 8/S hours CCTV q v5niT I
Tt (rr.fL) ff
ffl JT k I ilcN1 iJ ft
ftiT f[ 3fl-,Tm I fn
Management ct i
if ibra
• •.•
III
•1
U
••UU
U...
Ii
t4t *ek4'i
Tcltt cr'n n, rr ci
91t 5fl1Wf CI'IIft TT [1155 flT 3 t95 1TT 1[T *RT
Ic I
fi -
'5fl1 - ..,...
T. L
6 Ift't'I 'ttth
'5 11flM rI1r C C CP' J9tft PT f15P'f rrf wffi cn
tc" CWfl I fT fI, 1411
nrr I
fr i
1f TY it1tTM 19fT i
CNfl I
II
I 111111
I I UII
I I
••
IIIJ
I
wft cmicn z
1tI1 o—o8 rt 8¼,\b-o T1 wr vNhJ 1f5 ftN
5 WP C* I 4 1 1TYfl3Tko%
o-o8 CW'1f1 % 1 J1
'Scci ft I
4IZ f%n
n1T f;7jj frfT tftf cr rc rrt crn I rii
ff ri i
'3 iIiIt 8
51WP J C, C11
irc w11t I ' fir rr j
9,
311cT
To the best of our information and according to the explanations given to us, we certify
that, as reported on the attached status of compliance statement, the Company has
complied with the conditions of corporate governance stipulated in the above mentioned
BSEC notification dated 07 August 2012.
R—
AhMA Dated:06th November 2014
CEO & Principal Dhaka
A.Rahrnan & Associates
I!
7P 46wr
Joe-
Complied Not
Complied
1.1 Boards Size I
(number of Directors - minimum 5 and maximum 20)
1.2 (i) Independent Director
(at least one fifth of Directors should be Independent
Directors)
1.2 (ii) Independent Director
1.2 (ii) (a) Does not hold any share of the company
1.2 (ii) (b) Not a sponsor / spouse / family members
1.2 (ii) (c) Does not have any other relationship
1.2 (ii) (d) Not a Member, Director or Officer of any stock exchange
1.2 (ii) (e) Not a shareholder, director or Officer of any member of stock
exchange or an intermediary of capital market
1.2 (ii) (f) Not a partner or an executive or was not a partner or an
executive during the preceding 3 (three) years of the
concern company's statutory audit firm
1.2 (ii) (g) Not be an Independent Director in more than 3 (three) listed
companies
1.2 (ii) (h) Not been convicted by a court as a defaulter in payment of
any loan to a bank or a NBFI
1.2 (ii) (i) Not been convicted for a criminal offence involving moral
turpitude
1.2 (iii) Independent Director shall be a knowledgeable individual
1.2 (iv) Post of independent director not vacant for more than 90
days
1.2 (v) The Board shall lay down a code of conduct of all board
members and annual compliance of the code to be recorded
1.2 (vi) Tenure of office of an independent director shall be for a
period of 3 (three) years, which may be extended for 1 (one)
term only
1.3 Qualification of Independent Director (ID)
1.3 (i) Independent Director shall be appointed by the board of
directors
1.3 (ii) The person be a chartered accountants
1.3 (iii) In special cases the above qualification - - Not applicable
1.4 Chairman of the Board and Chief Executive Officer '1 MD acts as a Chief
Executive Officer
1.5 The Directors' Report to Shareholders
1.5 (i) Industry outlook and possible future developments in the
industry
1.5 (ii) Segment-wise or product-wise performance. - - Under process from
next year
I'
Compliance
(Putq in the appropriate
Condition No. I1i: •tyI
3 (iii)
3.1
3.1(i)
3.1 (ii)
3.1 (iii)
3.1 (iv)
I'
Compliance Status
(Put4 in the appropriate Remarks
Condition No. Title column) , (if any)
Not
Complied Complied.
I
3.1(v) The company secretary shall act as the secretary of the
Committee.
3.1 (vi) The quorum of the Audit Committee meeting shall not
constitute without at least 1 (one) independent director.
3.2 Chairman of the Audit Committee
3.2(i) The Board of Directors shall select 1 (one) member of the
Audit Committee to be Chairman of the Audit Committee,
who shall be an independent director.
3.2(u) Chairman of the audit committee shall remain present in the
Annual General Meeting (AGM).
3.3 Role of Audit Committee
3.3 (i) Oversee the financial reporting process.__
3.3 (ii) Monitor choice of accounting policies and principles.
3.3 (iii) Monitor Internal Control Risk management process.
3.3 (iv) Oversee hiring and performance of external auditors.
3.3 (v) Review along with the management, the annual financial
statements before submission to the board for approval.
3.3 (vi) Review along with the management, the quarterly and half
yearly financial statements before submission to the board
for approval.
3.3 (vii) Review the adequacy of internal audit function.
3.3 (viii) - Review statement of significant related party transactions
submitted by the management.
3.3 (ix) Review Management Letters! Letter of Internal Control
weakness issued by statutory auditors.
3.3 (x) When money is raised through Initial Public Offering
(IPO)/Repeat Public Offering (RPO)/Rights Issue the
company shall disclose to the Audit Committee about the
uses/applications of funds by major category (capital
expenditure, sales and marketing expenses, working capital,
etc), on a quarterly basis, as a part of their quarterly
declaration of financial results. Further, on an annual basis,
the company shall prepare a statement of funds utilized for
the purposes other than those stated in the offer
document/prospectus.
3.4 Reporting of the Audit Committee
3.4.1 Reporting to the Board of Directors
3.4.1 (I) The Audit Committee shall report on its activities to the
Board of Directors.
3.4.1 (ii) The Audit Committee shall immediately report to the Board
of Directors on the following findings, if any:--
3.4.1(ii)(a) Report on conflicts of interests
3.4.1(ii)(b) Suspected or presumed fraud or irregularity or material
defect in the internal control system
3.4.1(ii)(c) Suspected infringement of laws, including securities related
____________ laws, rules and regulations
3.4.1(ii)(d) any other matter which shall be disclosed to the Board of
Directors immediately.
3.4.2 Reporting to the Authorities .
If the Audit Committee has reported to the Board of Directors
about anything which has material impact on the financial
condition and results of operation and has discussed with
the Board of Directors and the management that any
rectification is necessary and if the Audit Committee finds
that such rectification has been unreasonably ignored, the
Audit committee shall report such finding to the
I r / a
Commission, upon reporting of such matters to the Board of
Directors for three times or completion of a period of 6 (six)
months from the date of first eporting to the Board of
Directors, whichever is earlier.
I M.H. Chowdhury
Member, Audit Committee
Md Mizanur Rahman FCA
Chairman, Audit Committee
2013-14 1 Page 32
I__11r
I IlIlli
I I 111
• II•Iw
I III
IIRUIE11
Monson
We have audited the accompanying financial statements of Libra Infusions Limited, which comprise the
Statement of Financial Position as at 30 June 2014, and the Statement of Comprehensive Income, Statement of
changes in equity and Statement cash flow for the year then ended, and a summary of significant accounting
policies and other explanatory notes.
Management's Responsibility
Management is responsible for the preparation and fair presentation of these financial statements in
accordance with Bangladesh Financial Reporting Standards, Securities and Exchange Commission Rules 1987,
Companies Act 1994 and other rules and regulation. This responsibility includes: designing, implementing and
maintaining internal control relevant to the preparation and fair presentation of financial statements that are
free from material misstatement, whether due to fraud or error; selecting and applying appropriate accounting
policies; and making accounting estimates that are reasonable in the circumstances.
Auditors' Responsibility
Our responsibility is to express an opinion on these financial statements based on our audit. We conducted our
audit in accordance with Bangladesh Standards on Auditing, those standards require that we comply with
ethical requirements and plan and perform the audit to obtain reasonable assurance whether the financial
statements are free from material misstatement. An audit involves performing procedures to obtain audit
evidence about the amounts and disclosures in the financial statements. The procedures selected depend on
the auditors judgment, including the assessment of the risks of material misstatement of the financial
statements, whether due to fraud or error. In making those risk assessments, the auditor considers internal control
relevant to the entity's preparation and fair presentation of the financial statements in order to design audit
procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the
effectiveness of the entity's internal control. An audit also includes evaluating the appropriateness of
accounting policies used and the reasonableness of accounting estimates made by management, as well as
evaluating the overall presentation of the financial statements. We believe that the audit evidence we have
obtained is sufficient and appropriate to provide a basis for our audit opinion.
Opinion
In our opinion, the financial statements give a true and fair view of the financial position of Libra Infusions Limited
as of 30 June 2014 and of its financial performance and its cash flows for the year then ended in accordance
with Bangladesh Financial Reporting Standards and comply with the Companies Act 1994, Securities and
Exchange Commission Rule 1987 and other applicable laws and regulations.
iii) The company's Statement of Financial Position, Statement of Comprehensive Income and Statement of
cash flow dealt with by the report are in agreement with the books of accounts;
iv) The expenditures incurred and payments made were for the purpose of the Company's business;
Dated, Dhaka:
28 October 2014 Atik Khaled Chowdhury
Chartered Accountants
MEN NOL P
ASSETS
This should be read in conjunction with the annexed notes to the Financial Statements.
Approved and authorised for issue by the Board of Directors and signed for and on behalf of the Board:
Jahangir Alam Dr. Roushon Alam Ayesha Alam
Company Secretary Managing Director & CEO Chairperson
Amount in Tako.
Particulars Notes
2013-2014 1 2012-2013
This should be read in conjunction with the annexed notes to the Financial Statements.
Approved and authorised for issue by the Board of Directors and signed for and on behalf of the Board:
Jahangir Alam
A,
Dr. Roushon Alam
cdpalvl-
Ayesha Alam
Company Secretary Managing Director & CEO Chairperson
u.i.i
NOON UN*
- I U....
•0
NONE No
Lee- ONE I
For: 2013-2014 Amount In Toka.
Revaluation General Retained
Particulars Share capital Surplus Reserve Total
Earnings
Balance as at 30 June 2013 12516,000 1,894,204,508 4,000,000 51,265,223 1,961,985,731
Adjustment for Depreciation on (2,261,262) 2,261,262 -
Revaluation Assets
For: 202-2013
Revaluation General Retained
Particulars Share capital Total
Surplus Reserve Earnings
Balance as at 30 June 2012 12,516,000 1,896,494,394 4,000,000 46,207,449 1,959,217,843
Adjustment for Depreciation on (2,289,886) 2,289,886 -
Revaluation Assets
Approved and authorised for issue by the Board of Directors and signed for and on behalf of the Board:
Jahangir Alam
A,Dr. Roushon Alam
Ayesha Alam
Company Secretary Managing Director & CEO Chairperson
___ II
I - ; i liii
II.
j.
, ml
lll
I1v
ra Infusions Limited
Statement of Cash Flows
for the year ended 30 June 2014
I!
L. TTI
MEMO 0
1. Company Profile
Libra Pharmaceuticals Limited was incorporated in Bangladesh as a Private limited Company
on 2 February 1976 under the Companies Act, 1913. It was converted into a Public Limited
Company in 1994 when it offered its share to the Public with the permission of the Bangladesh
Securities and Exchange Commission. Subsequently it was renamed as Libra Infusions Limited
on 27 October 1999. The shares of the company are publicly traded on the floors of Dhaka
Stock Exchange Limited and Chittagong Stock Exchange Limited.
Nature of Business
The company owns and operates modern Injectable Intravenous (l.V) Fluids, Pharmaceutical
products and Mineral Water manufacturing factories and it sells life saving products of different
quality / grades to Govt, Semi-Govt, Authorities Hospitals, Clinics and Licenses Pharmacies,
MMMMM
ILIII
I.
-BAS/BFRS NOTE
DESCRIPTION
REFERENCE
BAS 1 : Presentation of Financial Statements 8, 9,29
BAS 2 Inventories 18
BAS 7 Cash Flow Statements 28
BAS 8 Accounting Policies, Changes in Accounting
Estimates _and _Errors 17
BAS 10 : Events after the Balance Sheet Date 31
BAS 12Income
: Taxes 12.2.5
BAS 14 : Segment Reporting 27
BAS 16 : Property, Plant and Equipment 12.2.3
BAS 18 : Revenue 12.1
BAS 19 Employee Benefits 12.2.8
BAS 21 The effects of Changes in Foreign Exchange Rates 13
BAS 24 : Related Party Disclosures 30
BAS 27 Consolidated Financial Statements and
56
Accounting for Investment in Subsidiary
BAS 33 Earnings Per Share 12.2.10
-I!
UIUUU U
•1.I IU
u.a u
ago 0
iIIIII
MMMMMMM,10
MEN U&
I ..., .,
•iNONE
11111
•L•UU
4 I III
Depreciation on addition to Fixed Assets of Unit - 1 has been charged for six months
averagely and No depreciation has been provided on Unit-2 on during the year 2013-2014.
,
II
U
U&U
I.
EXEMN
UU
I
I
12.2.8 Employee Benefits
a) Provident Fund: The company has established a contributory provident fund scheme. The
fund is wholly administered by a Board of Trustees. No part of the fund is included in the assets
of the company.
b) Workers Profit Participation Fund and Welfare Fund: The company makes a regular
allocation of 5% on net profit before tax to this fund and payment is made to the workers and
staffs as per provision of the companies Profit under Labor Law 2006 chapter - 1 5.
r /
Annual Report 2Ol3-l4I Page 42I
I
#t
j
FIN
Actual results may differ from these estimates. Estimates and underlying assumptions are
reviewed on an ongoing basis. Any revision of accounting estimates are recognized in the
period in which the estimate is revised and in any future periods affected as required by BAS
8: "Net Income or Loss for the Period Fundamental Errors and Changes in Accounting
Policies".
18. Inventories
Inventories are stated at the lower of cost or net realizable value in compliance with the
requirements of Para 21 & 25 of BAS-2. The cost is calculated on weighted average method in
a consistent manner. Costs comprise of expenditure incurred in the normal course of business
in bringing out such inventories to its location and conditions. Where necessary, provision is
made for obsolete, slow moving and defective inventories if any) identified at the time if
physical verification of inventories. Cost of work in progress is determined at the basis of cost
of materials only.
A
Im. I
luil U
iii
iii...
ii'..'
t
Ii. Aftj
24. Impairment
In accordance with the provisions of BAS 36: "Impairment of Assets", the carrying amount of
non-financial assets, other than inventories is reviewed at each reporting date to determine
whether there is any indication of impairment. If any such indication exists, then the asset's
recoverable amount is estimated and impairment losses are recognized if profit and loss
account. No such indication of impairment has been raised till to date.
I
Annual Report 2Ol3-l4I Page 44I
I
I
0 NONE
• II
I
26. Provisions
A provision is recognized on the statement of financial position date if, as a result of post
events, the company has a present legal or constructive obligation that can be estimated
reliably, and it is probable that an outflow of economic benefits will be required to settle the
obligation.
Ii
a) C) - (N C) 0) N) (N '"
C) C) CO N Cl)
'C C) - .-- (0 (0 0) C CO
'C C U)
—C)C0N.
C)
c-a CC -C C) (0(0CO 0)
C) - N- N) .- 0 0) CO CO CO
H C (0 co N) N) (N C) C vi- (N C) -
C P a, T-,
C) 00
(N (N to 'C - -0 N
C C) (N 10 (0 C) 0 N.
0
E V)
N-. C co C) C) co 0
co -0 C) 0- C N-. N. N.
- (N -
C) •0- N- (N C) zr
o (N(N0)N--Q
H 'C CO (N U)
'C 'C (N U)
C) N- (N C r,-. C)
C C) C) CO C) C) N- U) U)
I
----6Kvi
Q)
0
0- 0 C) 'C LT)
N- C) 'C 'C 'C
U?
a) N 0) N- C14 N N
a
) C14 co LO 0- 'C 'C U)
CU C) 'C 'C C) (N CO C)
cC)Co
a)0)
Cl) C) 0 - CO
C) C) 'C (N
CD
a)
a) C) C) C) C) C) C)
(N C) C) C) C) C)
C) CO C) C) (0
-(NC)
0
— C) (0 0) 0) (0 (0 C) U) C
) 0 C) CO (vi
a) 'C C) C) N- 0) 0) (N co U) 'C i-j
2CN-CO C)N- (N N —)[)(N IT N.
a) C) C) C) CD N- 'C C) (0 C) C) 'C 4 N
a) (N C 'C CO 0 0) C) C) CO (vi
0(0 C)(0C)0)(0 (N cm,
C C) 10 'C 10 00 CO - C) C) C. N.
00 CO 0) -.- (N C) 'C - - -.0 -0
a) C) CO (N N. C) C) 0 CO
co
00 C) C) 0) CO in (4 0
C) CO
0) C) 0) CO co C) ,-0 N
(0C)N- C)N-(0 -U) (0
O C) (0 0)
N- C) C) 'C N- CO
0 'C N- U) C) (0 C) U) 0
— C) C) C_I (0 CD 0)
-C C) CC N- ,C'
C) C) (N (0 co co C) N. 'C (N to cvi
C) C) N- fl 0) (N C) N N- N- N.
N- N0(N IQ. N-
CO C C) CO N- IT (N v 0) 0) 0)
C) (N N- C) 0) CO 0 C) fl CD N C_I
OC) CO C)CO CN'C (N N-NJ ON
.4- 0) CC) (N It C) Ll) C) N- co 'C CO U)
0 N- (0 CD 0) (N C) N- (N C) C)
C C) CO (N N. 'C 'C CO (0
-- N
CZ C)
E
0
C C C
- (I) 0 0 -
C - C
C a) (I)
E 0- E
U) C) C)
C -- C -- N
cr 0 +
-D (I)
C 0 ? 0 a) a)
- .E u
C -C 0 C O .0
0 0 a) 0 C) 0
C'4EE
CD
cu
I I I
c's)
po
AnnualRo 13-14
U a hal
U III
I mass
Amount In Taka.
Notes Particulars 30.06.2014 I 30.06.2013
33 Inventories
This consists of as follows -
Raw Material 12,435,682 9,552,634
Packing Material 31 ,758,742 28,1 24,563
Work -in-Process 6,534,762 6,1 53,275
Finished Goods 18,159,772 17,815,563
Laboratory Chemicals & Accessories 3,765,481 3,270,668
Raw, Packing Materials in Transit 39,876,542 43,526,428
112,530,981 108,443,131
35 Accounts Receivable
This is unsecured, considered good and is falling due within one year -
14,943,267
Below 30 days 13,432,753
Within 30-60 days 4,037,396 3,629,283
Within 60-90 days 1,767,888 1,589,184
Above 90 days 8,217,723 7,387,049
Total 28,966,274 26,038,269
No amount was due from the directors', managing agent, managers and
other officers of the company and any of them severally or jointly with any
other person.
- - (
Amount In Taka.
Notes I Particulars
30.06.2014 1 30.06.2013
B. Deposits
This is arrived at as follows -
Security deposit I Earnest money 2,850,171 2,537,670
Lease rental to UCL 1,475,073 1,475,073
4,325,244 4,012,743
C. Prepayments
This is made - up as follows -
4,826,070
VAT (Value Added Tax) 1,125,583
Insurance Premium 538,270 214,115
5,364,340 1 ,339,698
Grand total (A+B+C) 71,488,546 52,425,660
0 Hopi
Ib.i
B. Long term Joan for Unit No-2 from Union Capital Ltd amounting to Taka.56,498,401 have
been secured against personal property of the Directors.
43 Other Liabilities
This consists of -
Unpaid Dividend 27,120,881 25,624,374
Employees, Provident Fund 10,568,075 9,836,109
Workers Profit Participation & Welfare fund 4,272,203 3,354,326
41,961,159 38,814,809
Short term Loan of Taka. 201,127,279 was taken from Al - Arafah Islami Bank Ltd. against
Finished goods. Raw & Packing materials which are payable currently,
II
IJI MAIN
rv
*
Amount In Taka.
Notes Particulars 30.06.2014 I 30.06.2013
31,330,338
45 Long Term Loan-Current Portion 37,253,170
This represents current portion of long term loans from financial institutions which
are repayable currently as follows:
This consists of -
A. For goods
This represents amount payable to regular suppliers of packing materials, promotional
materials etc. All suppliers were paid on a regular basis.
B. For Services
These are falling due within one year and arrived at as follows-
Telephone & fax 11,554 6,993
Gas & electricity 777,691 906,796
Insurance 134,260 156,345
Audit fee 60,000 60,000
Salary and wages 4,803,503 4,865,759
Travelling expenses - field forces 2,364,670 2,230,853
C & F charges 853,278 745,260
Others 1,254,327 1,403,396
10,259,283 10,375,402
,
/ ' .
/
/
/
Amount In Taka.
Notes Particulars 30.06.2014 I 30.06.2013
Mil
48 Taxation
This is arrived at as follows -
Balance 1 July 2013 9,083,599 8,554,098
Add: Current Tax 1,994,429 1,354,701
11 ,078,028 9,908,799
Income Tax Paid/Adjustment during this year (5,281 471 (825,200)
Balance at 30 June 2014 5,796,361 9,083,599
Amount In Taka.
Notes I Particulars 2013-2014 I 2012-2013
•H I
49 Net Sales Revenue
This is arrived at as follows -
Sales 325,1 37,328 263,223,522
Less: VAT (42,827,851) (35,903,807)
Net Sales revenue 282,309,477 227,3 1 9,715
Sales represent:
I. V Fluids Bag 4,858,727 4,783,006
Mineral Water Bottle 146,680
I, I
oil
!N moon
Ii •U•
L_ 0 No
NNAMMEN
•UUUMU
Amount In Taka.
Notes Particulars
2013-2014 I 2012-2013
50 Cost of Goods Sold
This is made - up as follows - Notes
Work in process -opening 6,1 53,275 6,042,577
Raw materials consumed 16,871,215 13,152,829
51
Packing materials consumed 52 122,560,949 97,202,074
Work in process -closing (6,534,762) (6,1 53,275)
Direct materials consumed 139,050,677 110,244,205
Direct labour 4,787,974 3,102,160
Manufacturing overhead 53 28,408,427 23,077,180
Depreciation 5,279,435 6,01 7,615
Cost of production (Material & Manufacturing Expenses) 177,526,513 142,441,160
Finished goods opening 17,815,563 16,543,302
195,342,076 158,984,462
Finished goods closing (18,159,772) (1 7,81 5,563)
177,182,304 141,168,899
Cost of sample (1,626,253) (852,643)
Cost of Goods Sold 175,556,051 140,316,256
Item wise quantity and value of Finished Goods Stock are as follows:
Amount In Taka.
Notes Particulars 2013-2014 I 2012-2013
53 Manufacturing Overhead
This consists of as follows -
Salary,wages and benefits 13,147,670 10,174,502
Indirect materials 1,010,286 1,393,410
Overtime 1,023,058 990,583
Travelling & conveyance 479,725 446,805
Printing & stationery 205,723 112,837
Repairs & maintenance 351,386 315,299
Telephone, telex & fax 141,041 89,160
Gas & electricity 8,635,722 7,041,944
0. Insurance 596,731 530,861
Automobile operating expenses 579,367 413,776
Canteen expenses 1,560,221 1,127,842
Municipal tax 375,408 210,621
Trade licence fee 302,089 229,540
28,408,427 23,077,180
Salary and wages includes Provident Fund contribution of Taka. 1,505,354 for
the workers.
pp.
Amount In Taka.
Notes Particulars
2013-2014 I 2012-2013
54 Administrative Expenses
This consists of as follows -
Salary and allowances
4,115,647 3,239,848
Directors remuneration 1,861,500 1,861,500
Directors fees 15,000 36,000
Office rent 240,000 240,000
Repairs and maintenance 337,058 358,292
Travelling & conveyance 408,307 444,761
Bank Charges 252,509 118,294
Office expenses 76,876 99,427
Fooding expenses 492,497 386,512
Automobile Operating expenses 211,105 231,648
Printing, stationery 172,545 115,480
Postage, telephone and telex 226,771 154,170
Electricity, gas and water 227,672 200,852
Insurance 184,408 105,311
Legal, professional & other service Charge 143,946 133,230
Membership fee 82,982 116,525
Audit fee 60,000 60,000
AGM expenses 214,963 200,743
Depreciation 199,732 198,882
Total 9,523,518 8,301,475
a. Audit fee represents Auditos remuneration for auditing the accounts of the
Company for the year ending 30 June 2014.
MMINK ii !T
'F SENN.
'NSM
son
ri
Amount In Taka.
Notes Particulars 2013-2014 1 2012-2013
56 Other Income
Operating Income - Sales of Fish fry 4,965,347 5,062,358
Less:
Operating Expenses - Purchase of post Larbac (912,348) (625,436)
Operating Expenses - Purchase of Fish Feed
(853,427) (602,639)
3,199,572 3,834,283
57 Finance Cost
This is made - up as follows -
Interest on Short Term Loan 2,076,569 1,533,759
Interest on Cash Credit 26,610,264 24,355,368
Interest on LTR 15,543,521 9,977,377
Interest on loan from P.F and Welfare fund 1,983,589 1,608,745
Total 46,213,943 37,475,249
The Company is paying interest © 11.50% on the balance of Workers' Profit Participation
& Welfare Fund and © 13.00% on Provident Fund for utilizing the amount.
58 Contribution to Workers' Profit Participation & Welfare Fund
This represents 5% of operating profit before tax after charging the contribution
provided as per provisions of the Companies Profit (Workers Participation) Act, 1968.
59 Current Tax
This represents estimated Income Tax Liability as follows:
27.50 % Income Tax on Taxable Profit of Taka 6,903,426 1,898,442 1,162,987
3 % Income Tax on Taxable Profit of Taka 3,199,572 95,987 191,714
1,994,429 1,354,701
A. Dividend - Proposed
The proposed dividend @ 20% i.e, Taka. 2.00 per share of Taka. 10 each has been
recommended by the Board of Directors subject to approval of shareholders.
During the year under review, a part of the balance of net profit though carried
forward in the Statement of Financial Position will be applied for payment of this
years cash dividend proposed by the Board of Directors @ Taka. 2.00 per share
and will be recognised as liability in the accounts as and when approved by the
shareholders in the Annual General Meeting. Total amount of proposed cash
dividend for the year 2013 - 2014 is calculated to Taka.25,03,200.00
61 Earnings Per Share (EPS)
Earning per share and its components have been defined in notes 12.2.10 The
computation of EPS is given below -
(A) The aggregate amounts paid to / provided for the officers of the company as
defined in the Securities and Exchange Rules 1987 are disclosed below:
lib-
I,Jv •
I
• -r
I !T ^:—Jks ;*w.
Capac Production Utilised
2013-2014 l.V Fluid Bags 10.00 49.40%
2012-2013 l.V Fluid Bags 10.00 4.58 45.80%
68 Credit Facilities
There was no credit facility available to the company under the contract but not
availed of as on 30 June 2014 other than bank credit facility and trade credit
available in the ordinary course of business.
ii
.,'
L • ui•
4
1-
r :•••
2013-2014 2012-2013
Unit
F.C. Taka F.C. Taka
- 226,799 17,768,842 168,526 13,734,195
(€) 36,000 3,863,682 - -
649,071 50,857,471 495,642 40,390,858
33,566 3,600,462 - -
£ - - 76,523 8,596,594
654,794 51,305,336 407,658 33,204,967
26,525 2,843,865 - -
79,050 10,276,500 19,045 2,139,515
73 Subsequent events
Subsequent events (disclosures under BAS 10 " Events after the Balance Sheet
date") There is no significant events subsequent to Balance Sheet date.
Jahangir Alam
/
Dr. Roushon Alam
Ownwll-
Ayesha Alam
Company Secretary Managing Director & CEO Chairperson
Dated, Dhaka:
28 October 2014
ii
LIBRA INFUSIONS LIMITED
Registered Office: 1/7, Mirpur Industrial Estate, Rupnagar
Section - 2, Dhaka -1216, Bangladesh
PROXY FORM
Note: A member entitled to attend and vote at the Annual General Meeting may appoint a Proxy to
attend and vote in his/her stead.The proxy form, duly completed must be deposited at Registered
Office of the Company not later than 48 hours before the time fixed for the meeting.
ATTENDANCE SLIP
I hereby record my presence at 36th ANNUAL GENERAL MEETING of Libra Infusions Ltd being held
on 28 December 2014 at 11.00 a.m at the Corporate Head Office, Building-2 (level-7), Mirpur- l/E,
Section-2, Rupnagar, Dhaka-1 216.
Signature
Note: The member attending the meeting in person or by proxy are requested to complete the
attendance slip and hand it over at the venue of the meeting
1 ii
ai
Dhaka
House"
Mymensingh Nawab Hab
Comilla
295, Maskanda, Shahbag, C
Bhuiyan Palace
(BSCIC) Area Tel: 8626267
Dhaka Road, Mobj1eøi9
Mymensingh.
Tel: 091-67633 Cell # 01977-292753
Mobile: 01977292688
Rajshahi Kushtia
House No.41 43,M k Rahim Sarak
ri
-V
el:U/2I-I243Y
Aobile: 01977296137
Libra Infusions Limited
P
In Obsession '.ith Quality ----- -